Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2008. Refer toTA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (which replaced NICE TA142) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | epoetin beta (NeoRecormon®) | |
| Formulation | solution for injection; powder and solvent for solution for injection | |
| Reference number | 128 | |
| Indication | Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy |
|
| Company | Roche Products Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 02/12/2003 | |
| Ratification by Welsh Government | 01/03/2004 | |
| Date of issue | 30/04/2004 | |
| NICE guidance | ||